当前位置: X-MOL 学术Lab Chip › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tumour-vessel-on-a-chip models for drug delivery
Lab on a Chip ( IF 6.1 ) Pub Date : 2017-08-17 00:00:00 , DOI: 10.1039/c7lc00574a
David Caballero 1, 2, 3, 4, 5 , Sophie M. Blackburn 1, 2, 3, 4 , Mar de Pablo 1, 2, 3, 4 , Josep Samitier 1, 2, 3, 4, 5 , Lorenzo Albertazzi 1, 2, 3, 4
Affiliation  

Nanocarriers for drug delivery have great potential to revolutionize cancer treatment, due to their enhanced selectivity and efficacy. Despite this great promise, researchers have had limited success in the clinical translation of this approach. One of the main causes of these difficulties is that standard in vitro models, typically used to understand nanocarriers' behaviour and screen their efficiency, do not provide the complexity typically encountered in living systems. In contrast, in vivo models, despite being highly physiological, display serious bottlenecks which threaten the relevancy of the obtained data. Microfluidics and nanofabrication can dramatically contribute to solving this issue, providing 3D high-throughput models with improved resemblance to in vivo systems. In particular, microfluidic models of tumour blood vessels can be used to better elucidate how new nanocarriers behave in the microcirculation of healthy and cancerous tissues. Several key steps of the drug delivery process such as extravasation, immune response and endothelial targeting happen under flow in capillaries and can be accurately modelled using microfluidics. In this review, we will present how tumour-vessel-on-a-chip systems can be used to investigate targeted drug delivery and which key factors need to be considered for the rational design of these materials. Future applications of this approach and its role in driving forward the next generation of targeted drug delivery methods will be discussed.

中文翻译:

肿瘤的单芯片肿瘤血管模型

由于其增强的选择性和功效,用于药物递送的纳米载体具有巨大的潜力来革新癌症治疗。尽管前景广阔,但研究人员在这种方法的临床翻译中取得的成功有限。这些困难的主要原因之一是,通常用于了解纳米载体行为并筛选其效率的标准体外模型不能提供通常在生物系统中遇到的复杂性。相反,尽管体内模型具有很高的生理性,但仍显示出严重的瓶颈,这威胁到所获得数据的相关性。微流体和纳米加工可以极大地帮助解决这一问题,提供3D高通量模型,与体内的相似度更高系统。特别地,肿瘤血管的微流模型可用于更好地阐明新型纳米载体在健康和癌性组织的微循环中的行为。药物输送过程中的几个关键步骤(例如外渗,免疫反应和内皮靶向)发生在毛细管流动下,并且可以使用微流控技术精确建模。在这篇综述中,我们将介绍如何使用芯片上肿瘤血管系统来研究靶向药物的输送以及合理设计这些材料需要考虑哪些关键因素。将讨论这种方法的未来应用及其在推动下一代靶向药物输送方法中的作用。
更新日期:2017-11-07
down
wechat
bug